Affimed Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Affimed N.V. (Nasdaq: AFMD) announced the successful closure of its public offering of 22,500,000 common shares at $4.00 per share. The underwriters exercised their option for an additional 3,375,000 shares, raising total gross proceeds to $103.5 million. The offering was facilitated by Jefferies LLC, SVB Leerink, Truist Securities, and Wells Fargo Securities, among others. Effective from April 6, 2022, the shelf registration statement allows the company to issue these securities. Funds raised will support Affimed's immuno-oncology initiatives.
- Total gross proceeds from the offering reached $103.5 million.
- The capital raised will be used to advance Affimed's immuno-oncology programs.
- The share offering may cause dilution of existing shareholder value.
HEIDELBERG, Germany, April 18, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the closing of its previously announced public offering of 22,500,000 common shares, at the public offering price of
Jefferies LLC, SVB Leerink, Truist Securities, Inc. and Wells Fargo Securities, LLC are acting as joint book-running managers and Berenberg Capital Markets LLC is acting as a co-manager of the offering. A shelf registration statement relating to these securities filed with the Securities and Exchange Commission (the “SEC”) was declared effective by the SEC on April 6, 2022. The offering was made only by means of a prospectus and prospectus supplement. A prospectus supplement and accompanying prospectus related to the offering have been filed with the SEC and are available at the SEC’s website located at www.sec.gov. Copies of the prospectus supplement and accompanying prospectus related to the offering may be obtained by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com, SVB Securities LLC, Attn: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at 1-800-808-7525, ext. 6105, or by email at syndicate@svbleerink.com, Truist Securities, Inc., Attention: Prospectus Department, 3333 Peachtree Road, NE, 11th Floor, Atlanta, Georgia 30326, by telephone at (800) 685-4786, or by email at TruistSecurities.prospectus@Truist.com, or Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 500 West 33rd Street, New York, New York 10001, by telephone at (833) 690-2713, or by email at cmclientsupport@wellsfargo.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK® platform predictably generates customized innate cell engager (ICE®) molecules, which use patients’ immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE®. Headquartered in Heidelberg, Germany, with offices in New York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients’ lives.
Forward-looking Statements
This press release contains statements that constitute “forward-looking statements,” including with respect to the proposed offering of common shares and the anticipated use of the net proceeds. No assurance can be given that the offering discussed above will be completed on the terms described, or at all, or that the net proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the company, including those set forth in the Risk Factors section of the company’s registration statement and preliminary prospectus for the company’s offering filed with the Securities and Exchange Commission (“SEC”). Copies are available on the SEC’s website, www.sec.gov. Given these risks, uncertainties, and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.
Investor Relations Contact
Alexander Fudukidis
Director, Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: +1 (917) 436-8102
Media Contact
Mary Beth Sandin
Vice President, Marketing and Communications
E-Mail: m.sandin@affimed.com
Tel: +1 (484) 888-8195
FAQ
How many shares did Affimed offer in April 2022?
What was the share price in Affimed's public offering?
What is the total amount raised in Affimed's April 2022 offering?
Who were the managers for Affimed's public offering?
What is the purpose of Affimed's public offering?
